{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"82.94","value":"40"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"0","value":"0"},{"groupId":"OG003","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"A responder is defined by more than 90% tumor necrosis at week 10. A non-responder has less than 90% necrosis or progressive disease before week 10.","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose-Finding Level 1 RT:\n\nAdult: Pazopanib 600 mg; Pediatric: Pazopanib 350 mg/m2","id":"OG000","title":"Dose-Finding Level 1 RT"},{"description":"Dose-Finding Level 2 RT:\n\nAdult: Pazopanib 800 mg; Pediatric: Pazopanib 450 mg/m2","id":"OG001","title":"Dose-Finding Level 2 RT"},{"description":"Regimen C: Radiation therapy plus pazopanib","id":"OG002","title":"Regimen C"},{"description":"Regimen D: Radiation therapy alone","id":"OG003","title":"Regimen D"}],"paramType":"NUMBER","populationDescription":"It was pre-specified to combine adult and pediatric participants for analysis as they received an equivalent dose of Pazopanib. There were no patients enrolled onto Dose Level 0 RT. 3 Regimen C patients excluded: 1 patient did not receive treatment and 2 missing review; 4 Regimen D patients excluded due to missing review.","reportingStatus":"POSTED","timeFrame":"Week 10 after induction","title":"Percentage of Radiotherapy Patients With Positive Pathologic Response at Week 10","type":"PRIMARY","unitOfMeasure":"Percentage of patients"}